Ascentage Pharma Group International
OTC:ASPHF
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.825
10.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
|
Ascentage Pharma Group International
HKEX:6855
|
17.3B HKD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
385.5B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.7B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
162.9B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.7B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.5B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.8B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
48.8B USD |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Ascentage Pharma Group International
Glance View
Ascentage Pharma Group International, a biopharmaceutical company stepping confidently onto the global stage, is driven by a mission to address unmet medical needs in the challenging realm of apoptosis-targeted therapies. Founded in 2009, with roots in both China and the United States, the company has honed its expertise in developing innovative small-molecule therapeutics. Its focus is on diseases inadequately treated by current standards, particularly cancers, hepatitis B, and age-related diseases. By concentrating on inhibiting protein-protein interactions that govern apoptosis, Ascentage Pharma employs sophisticated science to guide its research and development programs. This strategic focus on apoptosis, the programmed cell death process, enables the company to work on promising drug candidates that specifically target the pathways responsible for the survival and proliferation of malignant cells. Revenue generation for Ascentage Pharma is multi-faceted. Primarily, the company earns through partnerships, milestone payments, collaborative agreements, and licensing deals with larger pharmaceutical firms eager to leverage its unique expertise in apoptosis. In addition, its robust pipeline—comprising compounds at various stages of clinical development—provides strategic opportunities for monetization through out-licensing agreements once promising clinical data is established. By creating a symbiotic relationship with its partners, while also advancing its proprietary drug candidates towards commercialization, Ascentage Pharma not only progresses its significant research but also solidifies its financial foundation. The company’s growth is anchored in its ability to translate groundbreaking science into viable treatments that can crucially impact patients’ lives, paving a path to sustained financial and innovative success.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Ascentage Pharma Group International is -263.6%, which is below its 3-year median of -225%.
Over the last 3 years, Ascentage Pharma Group International’s Operating Margin has increased from -735.8% to -263.6%. During this period, it reached a low of -735.8% on Jun 30, 2022 and a high of -34% on Jun 30, 2024.